Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says

Executive Summary

Genentech seeks court order requiring Amgen to provide biosimilar manufacturing info so it can evaluate potential infringement; Supreme Court to hear Zarxio case on April 26.

Advertisement

Related Content

Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
Supreme Court Should Pass On Zarxio, Wait For Another Biosimilar Suit, Amgen Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel